OVERVIEW
Homocysteine is an amino acid found in the blood; levels are inversely correlated with folate levels. Homocysteine has been evaluated as a potential marker of cardiovascular disease (CVD) in the general population and as a potential risk marker among people with CVD. The association between homocysteine-lowering interventions and risk of CVD has also been examined.

MEDICAL CRITERIA
Not applicable

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
BlueCHiP for Medicare and Commercial Products
Measurement of plasma levels of homocysteine is considered not medically necessary in the screening, evaluation, and management of patients for cardiovascular disease due to the large amount of evidence that homocysteine-lowering interventions do not improve health outcomes.

COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for applicable not medically necessary benefits/coverage.

BACKGROUND
Homocysteine is a sulfur-containing amino acid that is rapidly oxidized in plasma into homocysteine and cysteine-homocysteine disulfide. Measurement of total plasma homocysteine is the sum of homocysteine and its oxidized forms. The laboratory test is referred to as either homocysteine or homocyst(e)ine.

Plasma levels of homocysteine have been actively researched as a risk factor for CVD, initially based on the observation that patients with hereditary homocystinuria, an inborn error of metabolism associated with high plasma levels of homocysteine, had a markedly increased risk of CVD. Subsequently, prospective epidemiologic studies were conducted to determine if an elevated plasma level of homocysteine was an independent risk factor for CVD and could be used to improve current risk prediction models.

Interest in homocysteine as a potentially modifiable risk factor has been stimulated by the epidemiologic finding that levels of homocysteine are inversely correlated with levels of folate. This finding has raised the possibility that treatment with folic acid might lower homocysteine levels and, in turn, reduce the risk of CVD. Therefore, homocysteine has potential utility both as a risk predictor and as a target of treatment. Determination of homocysteine concentration may be offered as a component of a comprehensive cardiovascular risk assessment that may include evaluation of small-density lipoproteins, subclassification of high-density lipoproteins, evaluation of lipoprotein (A), high-sensitivity C-reactive protein, and genotyping of apolipoprotein E.

Observational evidence generally supports the association of homocysteine levels with risk of CVD, especially in patients with preexisting vascular disease. However, evidence from randomized controlled trials (RCTs) does not support the hypothesis that lowering homocysteine levels by treatment with folate and/or B
vitamins improves cardiovascular outcomes. Numerous large RCTs and meta-analyses of these trials are consistent in reporting that homocysteine-lowering treatment is ineffective in reducing major cardiovascular events. Due to the large amount of evidence from placebo-controlled RCTs that homocysteine-lowering interventions do not improve health outcomes, routine testing for homocysteine in the screening, evaluation, or management of cardiovascular disease is considered not medically necessary.

**CODING**
The following CPT code is not medically necessary when filed with a diagnosis noted below:

83090  Assay of Homocystine

List of not medically necessary diagnosis codes:

**REFERENCES**

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). C-reactive protein as a cardiac risk marker (special report). TEC Assessments. 2002; Volume 17 Tab 23.


This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.